# Beijing Idmo Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-idmo-co

- Industry: Healthcare Specialists
- Headquarters: Beijing, China
- Website: www.idmo.com
- Latest round: Series A (Jan 10, 2019)
- Investors on record: 1

## About

Established in 2014 and based in Beijing, China, Beijing Idmo Co., Ltd. is a biotechnology company engaged in the development of innovative drug efficacy evaluation models. The company was founded by Dr. Peng Siying, who graduated from the Peking University Health Science Center and obtained a Ph.D. in Immunology from the Southern Illinois University School of Medicine, with postdoctoral experience at the Harvard Medical School-affiliated Immune Disease Institute. It has established a "Living Tumor Tissue Biobank" and collaborates with several top-tier hospitals in China for personalized cancer treatment. In January 2019, the company closed a round of series A+ funding.

offers a range of products and services aimed at improving the drug development process. The company has developed three main types of models: Patient-derived xenograft (PDX) models that maintain the original state of tumor tissue for high similarity to human tumors. IdealImmune, a tumor immuno-evaluation platform using dual humanized mice models for preclinical evaluation of immunotherapies and CAR-T therapies. Liver humanized mouse models for the study of liver cancer and infectious hepatitis, as well as for drug metabolism and toxicology tests. These models are designed to provide precise clinical medication guidance and contribute to personalized treatment plans for cancer patients.

The company generates revenue by providing its drug efficacy evaluation models and personalized treatment plans to pharmaceutical companies and healthcare institutions.

## Funding rounds

- Series A, Jan 10, 2019 — E-Town International Industrial Investment

## Investors

- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series A